Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Leonard, Sarah M ^a   Perry, Tracey ^a   Woodman, Ciarán B ^a   Kearns, Pamela ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTARABINE; DNA; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PYROSEQUENCING; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CYTARABINE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900336761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087475     Document Type: Article

References (21)

1. Burnett A, Wetzler M, Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29: 487-494.
2. Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17: 6417-6427.
3. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, et al. (2000) Low dose 5-aza-2-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18: 956-962. (Pubitemid 30123770)
4. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, et al. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.
5. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, et al. (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25: 3884-3891. (Pubitemid 47477265)
6. Christman JK (2002) 5-azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483-5495.
7. Mims A, Walker AR, Huang X, Sun J, Wang H, et al. (2013) Increased antileukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 27: 871-878.
8. Link PA, Baer MR, James SR, Jones DA, Karpf AR (2008) p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia. Cancer Res 68: 9358-9366.
9. Al-Salihi M, Yu M, Burnett DM, Alexander A, Samlowski WE, et al. (2011) The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics 6: 1021-1028.
10. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, et al. (2012) CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 26: 244-254.
11. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF (2010) Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28: 556-561.
12. Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, et al. (2011) Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118: 1472-1480.
13. Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, et al. (2013) Low dose decitabine in very high risk relapsed or refractory acute myeloid leukemia in children and young adults. Br J Haematol 161: 406-410.
14. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, et al. (2007) Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13: 4225-4232. (Pubitemid 47105987)
15. van Gosliga D, Schepers H, Rizo A, van der Kolk D, Vellenga E, et al. (2007) Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Experimental Hematology 35: 1538-1549. (Pubitemid 47419138)
16. Schuringa J, Schepers H (2008) Ex Vivo Assays to Study Self-Renewal and Long-Term Expansion of Genetically Modified Primary Human Acute Myeloid Leukemia Stem Cells. Leukemia 538: 287-300.
17. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, et al. (2013) Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 121: 1633-1643.
18. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, et al. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028.
19. Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, et al. (2013) Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk Res 37: 190-196.
20. Boehm TL, Drahovsky D (1982) Elevated level of enzymatic DNA methylation in cells treated with 1-beta-D-arabinofuranosylcytosine. Cancer Res 42: 1537-1540. (Pubitemid 12148802)
21. Nyce JW (1997) Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 386: 153-161.